Valuation: Assembly Biosciences, Inc.

Market Cap 543M 477M 442M 407M 768M 51.92B 785M 5.27B 2.06B 25.51B 2.04B 1.99B 88.2B P/E 2026 *
-25.3x
P/E 2027 * -9.56x
Enterprise Value 543M 477M 442M 407M 768M 51.92B 785M 5.27B 2.06B 25.51B 2.04B 1.99B 88.2B EV / Sales 2026 *
11.9x
EV / Sales 2027 * 16.8x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-1.61%
1 week-2.81%
Current month-1.89%
1 month+17.42%
3 months-5.14%
6 months-12.84%
Current year-20.73%
1 week 26.27
Extreme 26.27
29.94
1 month 22.58
Extreme 22.58
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Chief Financial Officer

-29 0.0002%
06-04Free

Director

8,000 0.0514%
06-04Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%-2.81%+43.79%+106.12% 543M
+0.44%+2.51%+4.36%+10.27% 50.73B
-1.57%-2.80%+383.82%+582.81% 39.73B
-0.14%+0.25%+27.49%-5.23% 34.69B
+1.76%+2.12%+21.44%+58.27% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.93%-3.38% - - 16.8B
-1.49%-4.92%+63.89%+119.25% 15.37B
+0.78%+0.20%+14.69%+17.08% 13.78B
-0.97%-4.02%+10.35%-31.69% 12.85B
Average -0.33%-1.00%+63.64%+98.73% 24.45B
Weighted average by Cap. +0.05%-0.38%+81.51%+122.97%

Financials

2026 *2027 *
Net sales 45.47M 39.95M 37.04M 34.06M 64.35M 4.35B 65.72M 442M 173M 2.14B 171M 167M 7.39B 32.25M 28.33M 26.27M 24.16M 45.64M 3.08B 46.61M 313M 123M 1.51B 121M 118M 5.24B
Net income -20.46M -17.98M -16.67M -15.33M -28.96M -1.96B -29.57M -199M -77.73M -961M -76.83M -75.16M -3.32B -56.38M -49.53M -45.93M -42.23M -79.79M -5.39B -81.48M -548M -214M -2.65B -212M -207M -9.16B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
13/07/26 $26.96 -1.61% 112,993
10/07/26 $27.40 -1.69% 169,991
09/07/26 $27.87 -2.99% 179,144
08/07/26 $28.73 -0.81% 135,958
07/07/26 $28.97 +0.24% 177,789
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.40USD
Average target price
50.00USD
Spread / Average Target
+82.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock